Detail of "83-74-9"

Reference

Rapid method for interrupting the narcotic addiction syndrome

Rapid method for interrupting the narcotic addiction syndrome. Lotsof, Howard S. (USA ). U.S. US 4499096 A 12 Feb 1985,4 pp. (English). (United States of America). CODEN: USXXAM. CLASS: ICM: A61K031-435. ICS: A61K031-475. NCL: 514214000. APPLICATION: US 83-553138 18 Nov 1983. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Ibogaine (I) [83-74-9] interrupts the physiol. and psychol. aspects of the narcotic addiction syndrome. A single oral treatment with I (6 to 19 mg/kg) disrupted heroin [561-27-3] use in humans for ~6 mo.

Fluorescence enhancement of several hallucinogenic drugs in cyclodextrin media

Fluorescence enhancement of several hallucinogenic drugs in cyclodextrin media. Jules, Oswald; Scypinski, Stephen; Love, L. J. Cline (Dep. Chem., Seton Hall Univ., South Orange, NJ 07079, USA). Anal. Chim. Acta, 169, 355-60 (English) 1985. CODEN: ACACAM. ISSN: 0003-2670. DOCUMENT TYPE: Journal CA Section: 64 (Pharmaceutical Analysis) The fluorescence characteristics of selected hallucinogenic drugs dissolved in solns. of a-cyclodextrin [10016-20-3] and b-cyclodextrin [7585-39-9] are reported. Fluorescence intensity enhancements in cyclodextrin media relative to aq. soln. range from 1.2 to 4.0, probably because inclusion of the drugs into cyclodextrin increases the quantum yield. Calibration graphs are linear over 2-3 orders of magnitude; limits of detection are 6-13 mg 1-1 for ibogaine [83-74-9] and N,N-dimethyltryptamine [61-50-7]. Mescaline [54-04-6] showed limits of detection in the 0.8-1.4 ppm range. The role of cyclodextrin in enhancing the fluorescence intensities and some of the criteria for this fluorescence enhancement are discussed.